Pyxis Chops Development On Preclinical Assets

Pyxis Chops Development On Preclinical Assets
  • Pyxis Oncology Inc PYXS is shifting its short-term emphasis to focus on two programs.
  • “We have elected to sharpen our near-term focus on the clinical execution of our two most advanced programs, anti-EDB Antibody Drug Conjugate (ADC), PYX-201, and anti-Siglec-15 monoclonal antibody (mAb), PYX-106,” CEO Lara Sullivan said.
  • The chief executive also added that the biotech is looking at leveraging its “industry network” to identify and facilitate opportunities for strategic partnerships.
  • The company is pausing development on two candidates — an anti-CD123 ADC called PYX-203 and an anti-KLRG1 I/O drug, PYX-102. 
  • The biotech added that it remains optimistic about the long-term future of those candidates and is open to outside collaboration or licensing if not further development in-house.
  • Development for PYX-202, another ADC that targeted DLK1, has officially been stopped after Pyxis reviewed data collected from toxicology studies that the company announced earlier this year.
  • Pyxis reported a cash amount of around $223 million, which, by their estimation, should keep the company going through the 2H of 2024.
  • Price Action: PYXS shares are down 2.40% at $2.85 during the market session on the last check Monday.

Posted In: BriefsBiotechEarningsNewsPenny StocksHealth CareGeneral